{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:06:21Z","timestamp":1779944781120,"version":"3.53.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the screening value of the triglyceride-glucose index (TyG) combined with the systemic immune-inflammation index (SII) for diabetic kidney disease (DKD) in hospitalized patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 335 hospitalized T2DM patients (175 with DKD, 160 without DKD) at Yancheng Third People\u2019s Hospital from 2022 to 2024. DKD was defined according to KDIGO 2022 criteria persistent urinary albumin-to-creatinine ratio (UACR) \u226530 mg\/g and\/or estimated glomerular filtration rate (eGFR) &amp;lt;60 mL\/min\/1.73m\u00b2 lasting for &amp;gt;3 months. Clinical data were collected, and the TyG index and SII were calculated. Due to severe skewness, SII was log10-transformed (lgSII). Logistic regression was used to construct five progressive prediction models. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), DeLong\u2019s test, calibration curves, and decision curve analysis (DCA). Internal validation was performed via Bootstrap (2000 repetitions) and 5-fold cross-validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TyG and lgSII were significantly higher in the DKD group compared to the non-DKD group (P&amp;lt;0.001). The final streamlined model (including TyG, lgSII, diabetes duration, systolic blood pressure, and HbA1c) achieved an AUC of 0.850. The Hosmer-Lemeshow test indicated good calibration (P\u00a0=\u00a00.257). The optimal cut-off values were TyG &amp;gt;10.03 and lgSII &amp;gt;2.76, yielding a sensitivity of 74.3% and a specificity of 85.0%. The high-risk group (both indicators above cut-offs) had a DKD prevalence of 96.8%. Bootstrap validation yielded a mean AUC of 0.855, indicating robust model stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of TyG and SII demonstrates favorable screening efficacy and model stability for identifying DKD among hospitalized T2DM patients. This model provides preliminary evidence for a low-cost, readily available tool for rapid risk stratification, but requires external validation before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1854268","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:45:09Z","timestamp":1779943509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical study on the value of TyG index combined with systemic immune-inflammation index for screening hospitalized patients with type 2 diabetic kidney disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiuyun","family":"Song","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory,Yancheng Third People\u2019s Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory,Yancheng Third People\u2019s Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory,Yancheng Third People\u2019s Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory,Yancheng Third People\u2019s Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.122.000560","article-title":"Pharmacological targeting of mitochondria in diabetic kidney disease","volume":"75","author":"Cleveland","year":"2023","journal-title":"Pharmacol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/nep.13860","article-title":"Update on diagnosis, pathophysiology, and management of diabetic kidney disease","volume":"26","author":"Sugahara","year":"2021","journal-title":"Nephrology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial2030038","article-title":"The epidemiology of diabetic kidney disease","volume":"2","author":"Hoogeveen","year":"2022","journal-title":"Kidney Dialysis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20050","article-title":"Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and type 2 diabetes","volume":"297","author":"Zannad","year":"2025","journal-title":"J Internal Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.598910","article-title":"Epidermal growth factor receptor: a potential therapeutic target for diabetic kidney disease","volume":"11","author":"Sheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208887","article-title":"Performance and pitfalls of the tools for measuring glomerular filtration rate to guide chronic kidney disease diagnosis and assessment","volume":"76","author":"Gama","year":"2023","journal-title":"J Clin Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","article-title":"Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations","volume":"21","author":"Tao","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12933-023-01973-7","article-title":"Triglyceride-glucose index and heart failure: a systematic review and meta-analysis","volume":"22","author":"Khalaji","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090305","article-title":"Association of the systemic immune-inflammation index (SII) and clinical outcomes in patients with stroke: a systematic review and meta-analysis","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2140535","article-title":"The systemic immune-inflammation index in predicting sepsis mortality","volume":"135","author":"Mangalesh","year":"2023","journal-title":"Postgraduate Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2020.8184","article-title":"Inflammation and oxidative stress in chronic kidney disease and dialysis patients","volume":"35","author":"Ebert","year":"2021","journal-title":"Antioxidants Redox Signaling"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s286565","article-title":"Comparison of novel metabolic indices in estimation of chronic kidney diseases in a southern Chinese population","volume":"13","author":"Chen","year":"2020","journal-title":"Diabetes Metab Syndrome Obes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1728293","article-title":"Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers","volume":"16","author":"Meng","year":"2025","journal-title":"Front Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01777-9","article-title":"Real-world diagnosis and treatment of diabetic kidney disease","volume":"38","author":"Rodriguez","year":"2021","journal-title":"Adv Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein\u2013creatinine ratio or urine dipstick protein to urine albumin\u2013creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant\u2013based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Internal Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48333","article-title":"Urinary albumin-to-creatinine ratio in normal range, cardiovascular health, and all-cause mortality","volume":"6","author":"Mahemuti","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01609-3","article-title":"Triglyceride glucose index for the detection of diabetic kidney disease and diabetic peripheral neuropathy in hospitalized patients with type 2 diabetes","volume":"15","author":"Tu","year":"2024","journal-title":"Diabetes Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323174","article-title":"Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s40001-023-01529-1","article-title":"Systemic immune-inflammation index (SII) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in the general population","volume":"28","author":"Wang","year":"2023","journal-title":"Eur J Med Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s318255","article-title":"Relationship between the TyG index and diabetic kidney disease in patients with type-2 diabetes mellitus","volume":"14","author":"Lv","year":"2021","journal-title":"Diabetes Metab Syndrome Obes"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-5424916\/v1","volume-title":"C-peptide involvement in the progression of type 2 diabetes mellitus through triglyceride-centered lipid metabolism disorders","author":"Li","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13040455","article-title":"Oxidative stress: a culprit in the progression of diabetic kidney disease","volume":"13","author":"Wang","year":"2024","journal-title":"Antioxidants"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262211033","article-title":"The inflammatory cell death in diabetic kidney disease: integrating multifactorial mechanisms into novel therapeutics","volume":"26","author":"Fang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/dom.16359","article-title":"Developments in albuminuria testing: a key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease\u2014a practical update for clinicians","volume":"27","author":"Beernink","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12916-022-02537-4","article-title":"From screening to treatment: the new landscape of diabetic kidney disease","volume":"20","author":"Cervantes","year":"2022","journal-title":"BMC Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.semnephrol.2020.01.010","article-title":"It takes two to tango: the role of dysregulated metabolism and inflammation in kidney disease development","volume":"40","author":"Quinn","year":"2020","journal-title":"Semin Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1854268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:45:19Z","timestamp":1779943519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1854268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":27,"alternative-id":["10.3389\/fendo.2026.1854268"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1854268","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1854268"}}